{"title":"Efanesoctocog阿尔法。重组凝血因子VIII fc -血管性血友病因子融合蛋白,治疗血友病A","authors":"L. Villarreal-Martínez, P. L. Zamora-Martinez","doi":"10.1358/dof.2022.47.10.3455369","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efanesoctocog alfa. Recombinant coagulation factor VIII Fc-von Willebrand factor fusion protein, Treatment of hemophilia A\",\"authors\":\"L. Villarreal-Martínez, P. L. Zamora-Martinez\",\"doi\":\"10.1358/dof.2022.47.10.3455369\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":11366,\"journal\":{\"name\":\"Drugs of The Future\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drugs of The Future\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1358/dof.2022.47.10.3455369\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs of The Future","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1358/dof.2022.47.10.3455369","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
期刊介绍:
A leading international, peer-reviewed biomedical research journal publishing articles on topics emerging from the confluence of fields including chemistry, biology, pharmacology, genomics and medicine, and addressed to scientists and researchers involved in drug design, discovery and development, target identification and validation, and the preclinical and clinical development of treatments for common as well as rare and neglected diseases and conditions.
The journal publishes monographs containing comprehensive product information on new compounds in development, including synthesis, preclinical pharmacology, pharmacokinetics and metabolism, safety, clinical studies and drug interactions, as well as review articles on a variety of topics, congress and meeting reports.